Abstract:Vascular endothelial growth factor receptor 3(VEGFR-3),a specific receptor of vascular endothelial growth factor C(VEGF-C),is a new member of tyrosine kinase receptor family.VEGFR-3 is consisted of extracellular,transmembrane and intracellular regions.The extracellular region comprises of seven immunoglobin-like domains,among which the first three domains(1-3Ig) play especially important roles in VEGF-C/VEGFR-3 signaling pathway,because these domains are responsible for the binding between VEGFR-3 and VEGF-C.Lymphatic endothelial progenitor cells(LEPCs) are mainly localized to the bone marrow,but can be released from bone marrow into diseased tissues in case of inflammation,ischemia or tumour,etc,and differentiated into lymphatic endothelial cells(LEC) to participate in the lymphangiogenesis in tumour tissues.As VEGF-C/VEGFR-3 signaling pathway is critical for the differentiation of LEPCs into LEC in tumour tissue,blockage of this signaling pathway will therefore be useful for inhibiting lymphangiogenesis and for the anti-tumour treatment.It is suggested that soluble VEGFR-3 can interfere with the binding between the VEGF-C and membrane-bound VEGFR-3,and thus can block VEGF-C/VEGFR-3 signaling pathway.In this study,we investigate the secretion of soluble VEGFR-3 proteins in LEPCs after transfected with recombinant adenovirus containing VEGFR-3(1-3Ig) gene of BABL/c mouse and the biological activity of the secreted protein.The gene encoding VEGFR-3(1-3Ig) was obtained through nested RT-PCR from BABL/c mouse placenta,and human CD33 signal peptide was added to the N-terminal of the PCR product through recombinant PCR technique.Then the gene fragment was cloned into the adenovirus shuttle plasmid pDC316-IRES-EGFP.After confirmed by restriction enzyme digestion and DNA sequencing,the recombinant adenovirus vector carrying VEGFR-3(1-3Ig) was transfected into 293-cells together with the packing vector to produce the recombinant adenovirus.The recombinant adenovirus was used to transfect LEPCs,and ELISA was employed to quantify the amount of soluble VEGFR-3 protein in the culture medium from transfected LEPCs.The biological activity of the soluble VEGFR-3 was determined by its ability to neutralize VEGF-C.Results showed that an adenovirus expression vector for soluble VEGFR-3 was successfully constructed,which can produce high titer recombinant adenovirus containing VEGFR-3(1-3Ig) of BABL/c mouse in 293-cells after transfection with packing vector.On transfection with the recombinant adenovirus carrying VEGFR-3(1-3Ig),LEPCs can release soluble VEGFR-3 as determined by ELISA,and the released VEGFR-3 can neutralize VEGFC efficiently.In conlusion,we demonstrated that LEPCs can express and secrete soluble VEGFR-3 protein after transfected with recombinant adenovirus containing BABL/c mouse VEGFR-3(1-3Ig) gene,and the released soluble VEGFR-3 protein to neutralize VEGF-C.This study has laid a foundation for the application of VEGFR-3 gene-transfected LEPCs in the antitumor treatment.

Inhibition of Lymphangiogenesis of Endothelial Progenitor Cells with Vegfr-3 Sirna Delivered with Pei-Alginate Nanoparticles

Abstract 3255: Inhibition of Intracrine VEGF Signaling Prevents Colorectal Cancer Cell Migration and Invasion

Construction of pcDNA3-Endo eukaryon expression plasmid and angiogenesis inhibition in vitro

Cd34(+)Vegfr-3(+) Progenitor Cells Have A Potential to Differentiate Towards Lymphatic Endothelial Cells

Inhibition of Human Hepatocellular Carcinoma Tumor Angiogenesis by Sirna Silencing of VEGF Via Hepatic Artery Perfusion.

Inhibition Of Angiogenesis By A Novel Neutralizing Antibody Targeting Human Vegfr-3

Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.

Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor.

FP3: a Novel VEGF Blocker with Antiangiogenic Effects in Vitro and Antitumour Effects in Vivo

Hvegf Sirna Inhibits Initial Growth of A549 Tumor Cells in Nude Mice and Angiogenesis on CAM Assay

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Investigation of Targeting Relationship Between Micro-Rna-22 and Vegfr3 in Lung Squamous Cell Carcinoma

A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Efficiently Inhibits Growth of VX2 Cells and VX2 Tumor Model of Hepatocellular Carcinoma in Rabbit by Transarterial Embolization-Mediated Sirna Delivery.

Anti-Angiogenic Efficacy of 5 '-Triphosphate Sirna Combining Vegf Silencing and Rig-I Activation in Nsclcs

VEGF Sirna Delivered by Polycation Liposome-Encapsulated Calcium Phosphate Nanoparticles for Tumor Angiogenesis Inhibition in Breast Cancer

Targeted Anti-Cancer Therapy: Co-Delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-Modified Lipid Nanoparticles for Enhanced Anti-Angiogenic Efficacy

VEGFR-3 Gene Transfection for Its Soluble VEGFR-3 Release in Lymphatic Endothelial Progenitor Cells

Efficient Sirna Delivery Using Peg-Conjugated Pamam Dendrimers Targeting Vascular Endothelial Growth Factor In A Cocl2-Induced Neovascularization Model In Retinal Endothelial Cells

Inhibition of K562 Leukemia Angiogenesis and Growth by Expression of Antisense Vascular Endothelial Growth Factor (VEGF) Sequence

Anti-tumor effects of vascular endothelial growth factor/vascular endothelial growth factor receptor binding domain-modified chimeric antigen receptor T cells

Nanocomposite-siRNA approach for down-regulation of VEGF and its receptor in myeloid leukemia cells